Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Obesity & Overweight, Mobility Disability, HOMA-IR

In brief

The primary objective of this study is to assess the effect of enobosarm on total body weight

Key facts

Study ID: NCT07446998
Run by: Veru Inc.
People needed: 200
Starts: 2026-03-26
Expected to finish: 2027-12-01
Last updated by the study team: 2026-07-01

Who can join

Age: 65 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subjects accepted for this study must:
Provide informed consent from the subject or the subject's legally authorized representative
Be able to communicate effectively with the study personnel
Be ≥65 years of age at the time of screening
For Female Subjects Menopausal status
Be postmenopausal as defined by either:
one year or more of amenorrhea
surgical menopause with bilateral oophorectomy
Be premenopausal or perimenopausal with a negative pregnancy test.
If subject is of child bearing potential, the subject must agree to use acceptable methods of contraception: If female study participant could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 30 days following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization of male partner (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
If female study participant has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
If female study participant has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used For Male Subjects
Subject must agree to use acceptable methods of contraception:
If the study subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 30 days following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner uses oral contraceptives (combination estrogen/progesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam/gel/film/cream/suppository)
If female partner of a study subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam/gel/film/cream/suppository) should also be used
If female partner of a study subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam/gel/film/cream/suppository) should also be used
Female partner is menopausal as defined above
Medically indicated for use of semaglutide for weight reduction 6. Have BMI ≥35 7. Consents to continue treatment with semaglutide for up to 476 days under this protocol. 8. Subject is willing to comply with the requirements of the protocol through the end of the study 9. The patient is able to swallow oral medications 10.The patient is able to complete the physical function (stair climb) assessment 11.Maximum weight at screening of 350lbs as per DXA requirements

You may not qualify if…

Any of the following conditions are cause for exclusion from the study:
Known hypersensitivity or allergy to enobosarm or a GLP-1 receptor agonist
Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 as measured using the chronic kidney disease-epidemiology collaboration (CKD-EPI) calculation (patients with mild and moderate renal failure are not excluded from participation in this study)
Treatment with any investigational product within < 5 half-lives for each individual investigational product OR within 30 days prior to randomization
Major surgery (the surgery poses a significant risk to patients life and requires general anesthesia) within 30 days prior to randomization
Planned major surgery during the course of the study or any cosmetic surgery potentially impacting body composition, e.g., liposuction, implants, or removal of any current implants
Testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), myostatin inhibitors, apelin receptor agonists, or antiandrogens (flutamide, bicalutamide, abiraterone, enzalutamide, apalutamide, or darolutamide).
Previous therapy with testosterone and testosterone-like agents is acceptable with a 30-day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the Medical Monitor) or any other androgenic agent.
An abnormal ECG result which, based on the investigator's clinical judgment, would place the subject at increased medical risk. A QTcF >450 ms for males and >460 ms for females is also exclusionary from this protocol.
Concurrently participating in any other interventional or treatment clinical trial.
Pre-existing liver disease (hepatitis B, uncontrolled hepatitis A, hepatitis C, autoimmune hepatitis, liver cancer, alcohol-associated cirrhosis, alcohol-associated hepatitis, alcohol-associated fatty liver)
Baseline ALT or AST >3x upper limit of normal
Baseline total bilirubin levels >upper limit of normal (except in cases of Gilbert's Syndrome)
History of acute pancreatitis within one year of screening or history of chronic pancreatitis
Severe gastrointestinal disease, including gastroparesis
Major depressive disorder diagnosed within 2 years prior to screening (NOTE: a diagnosis of major depressive disorder ≥2 years prior to screening that is stably managed [with or without pharmacological intervention] without additional exclusionary history are not excluded from the study), history of other severe psychiatric disorder, including schizophrenia and bipolar disorder, any lifetime history of suicide attempt, or with suicidal ideation or behavior within 1 month prior to screening.
Patient Health Questionnaire score >15 or any suicidal ideation of type 4 or type 5 on the Columbia-Suicide Severity Rating Scale
Monogenic or syndrome obesity, and endocrine causes of obesity (such as untreated hypothyroidism or Cushing's syndrome), and obesity caused by medications that cause weight gain
Prior bariatric surgery or weight loss devices unless removed for ≥1 year prior to screening for this study.
Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥6.5%
Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed with antidiabetic medication or non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion as long as other study criteria are met and the patient has not progressed to a diagnosis of diabetes.
Creatine kinase >1.5x ULN
Any condition that is exclusionary for use of semaglutide (generally WEGOVY) in the patient. See the WEGOVY Prescribing Information. The following contraindications are listed in the WEGOVY prescribing information:
Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
Known hypersensitivity to semaglutide or any of the excipients in WEGOVY.

Where it is running

DM Clinical - Seattle — Seattle, Washington, United States (enrolling)
DM Clinical Research - MIA — Doral, Florida, United States (enrolling)
Universal Axon Clinical Research (Rovia - UACR) — Doral, Florida, United States (enrolling)
Paramo Health — Miami, Florida, United States (enrolling)
IMIC Research a Rovia Clinical Research Company — Miami, Florida, United States (enrolling)
Paramo Health — Miami, Florida, United States (enrolling)
DM Clinical Research - Phoenix — Phoenix, Arizona, United States (enrolling)
Pennington Biomedical Research Center — Baton Rouge, Louisiana, United States (enrolling)
Centennial Medical Group (CMG) — Columbia, Maryland, United States (enrolling)
SKY Integrative Medical Center — Ridgeland, Mississippi, United States (enrolling)
ALSA Research — New York, New York, United States (enrolling)
Coastal Research Institute, LLC — Fayetteville, North Carolina, United States (enrolling)
DM Clinical - Dallas — Irving, Texas, United States (enrolling)
UD Research — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.